Latest Conference

Julie Khlevner, MD, AGAF, highlights that FDA approval of linaclotide provides the first pharmacologic therapy for pediatric IBS-C.

At NASPGHAN 2025, investigators presented 52-week safety data from an ongoing phase 3 trial of linaclotide, the first approved treatment for patients aged 7 and older with IBS-C.

The American Academy of Pediatrics updates guidelines, allowing doxycycline use in young children for tick-borne infections, enhancing treatment options.

A health system–wide lipid screening pathway significantly increased pediatric screening rates across a large primary care network.

A multicenter study from NASPGHAN 2025 highlights geographic and immune-driven variations in pediatric H. pylori infection across the Americas.

Ruth Lynfield, MD, discusses an approach clinicians can take in counseling parents who may have concerns about vaccines.

“There was no effect of lenacapavir on either estrogen containing or testosterone-containing regimens, no decrement in estradiol or testosterone levels," said Jill Blumenthal, MD, MAS.

Anne Kasmar, MD, MSc, highlighted how AMR innovation relies on immune-based science, novel modalities, and strong regulatory collaboration at IDWeek 2025.

Key highlights from the conference included public health, advocacy for vaccines, and artificial intelligence.

New one-year data showed that baricitinib continued scalp, eyebrow, and eyelash regrowth in adolescents with severe alopecia areata.

A single injection once per 8 weeks vs once per 4 weeks demonstrated similar levles of skin clearance, for AD patients 12 years and older, according to a Fall Clinical announcement.

New patient- and caregiver-reported outcomes across 3 phase 3 trials demonstrated improved itch and reduced impact of AD on sleep in patients 2 years and older.

In this Q&A, Abby Nerlinger, MD, breaks down how pediatricians can provide detailed care for children with military connections, based on a session presented at the 2025 AAP National Conference & Exhibition.

In this brief clip, Lori Handy, MD, MSCE, of CHOP, explains the evolving dynamic of trust between patients, parents, and health care.

Lori Handy, MD, MSCE, discussed how clinicians can strengthen vaccine communication by engaging openly and partnering with trusted community messengers.

Nicholas P. Marshall, MD, FAAP, discussed how generative AI can help streamline infectious disease workflows and enhance evidence-based care at IDWeek 2025 in Atlanta.

Yohei Doi, MD, IDWeek chair, Infectious Diseases Society of America, provides some insights on the happenings at this year’s event from Atlanta, Georgia.

* Generic lenacapavir could be produced for $25 per person per year at scale, according to an analysis presented at IDWeek 2025 in Atlanta.